Harrow, Inc. (HROW)
| Market Cap | 1.15B +25.0% |
| Revenue (ttm) | 268.68M +26.2% |
| Net Income | -14.96M |
| EPS | -0.40 |
| Shares Out | 37.28M |
| PE Ratio | n/a |
| Forward PE | 35.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 746,940 |
| Open | 31.07 |
| Previous Close | 31.21 |
| Day's Range | 30.56 - 31.68 |
| 52-Week Range | 25.21 - 54.85 |
| Beta | 0.34 |
| Analysts | Strong Buy |
| Price Target | 67.75 (+119.26%) |
| Earnings Date | May 11, 2026 |
About HROW
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for p... [Read more]
Financial Performance
In 2025, Harrow's revenue was $272.30 million, an increase of 36.41% compared to the previous year's $199.61 million. Losses were -$5.14 million, -70.60% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for HROW stock is "Strong Buy." The 12-month stock price target is $67.75, which is an increase of 119.26% from the latest price.
News
Harrow CEO buys $302K, CFO buys $104.7K in common stock
In regulatory filings, Harrow (HROW) disclosed that its CEO, Mark Baum, bought 10,000 shares of common stock and CFO Andrew Boll bought 3,500 shares of common stock on May 14th…
Harrow price target lowered to $60 from $65 at B. Riley
B. Riley lowered the firm’s price target on Harrow (HROW) to $60 from $65 and keeps a Buy rating on the shares. Harrow saw Q1 results overshadowed by weaker VEVYE…
Harrow price target lowered to $88 from $91 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse lowered the firm’s price target on Harrow (HROW) to $88 from $91 and keeps an Overweight rating on the shares.
Harrow Earnings Call Transcript: Q1 2026
Q1 revenue was $44.2M, impacted by an $8M VEVYE gross-to-net adjustment, but demand for key products remains strong. Full-year guidance of $350M–$365M is reaffirmed, with sequential growth and new product launches expected to drive a stronger second half.
Harrow Earnings release: Q1 2026
Harrow released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Harrow Quarterly report: Q1 2026
Harrow has published its Q1 2026 quarterly earnings report on May 12, 2026.
Harrow Shareholder letter: Q1 2026
Harrow has published a letter to shareholders covering Q1 2026, which was released on May 12, 2026.
Harrow Slides: Q1 2026
Harrow has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Harrow reports Q1 EPS (74c) vs. (50c) last year
Reports Q1 revenue $44.2M vs. $47.83M last year. “The demand for Harrow’s (HROW) key products has never been stronger, and our visibility into our demand trajectory – across our portfolio…
Harrow Announces First Quarter 2026 Financial Results
First Quarter 2026 and Selected Highlights: VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE demand gr...
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its fina...
Harrow Proxy statement: Proxy filing
Harrow filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Harrow Proxy statement: Proxy filing
Harrow filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Harrow announces issuance of J-Code for Iopidine 1%
Harrow (HROW) announced that Iopidine 1% has been assigned a permanent J-Code by the Centers for Medicare & Medicaid Services, CMS. Effective July 1, 2026, Iopidine 1% will be reimbursed…
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE® 1% (apracloni...
Harrow selects LogiCare3PL as distribution partner
LogiCare3PL announced it has been selected by Harrow (HROW) as a distribution partner for Harrow’s portfolio of ophthalmic disease management solutions. Effective February 1, 2026, LogiCare3PL is prov...
LogiCare3PL Selected as Distribution Partner by Harrow
OLIVE BRANCH, Miss., April 14, 2026 /PRNewswire/ -- LogiCare3PL today announced it has been selected by Harrow, Inc. (Nasdaq: HROW) as a distribution partner for Harrow's portfolio of ophthalmic disea...
Harrow management to meet virtually with BTIG
Virtual Meeting to be held on April 16 hosted by BTIG.
Harrow management to meet virtually with BTIG
Virtual Meeting to be held on April 14 hosted by BTIG.
Harrow price target lowered to $65 from $74 at B. Riley
B. Riley analyst Mayank Mamtani lowered the firm’s price target on Harrow (HROW) to $65 from $74 and keeps a Buy rating on the shares. The firm’s FY26 revenue estimate…
Harrow price target lowered to $65 from $74 at B. Riley
B. Riley analyst Mayank Mamtani lowered the firm’s price target on Harrow (HROW) to $65 from $74 and keeps a Buy rating on the shares. The firm’s FY26 revenue estimate…
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private o...
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, su...
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstra...
Harrow Transcript: Leerink Global Healthcare Conference 2026
Strong five-year growth continues with record revenues and EBITDA, driven by a diverse ophthalmic portfolio and new product launches. Key products like VEVYE, IHEEZO, and TRIESENCE are expanding market share, while biosimilars and pipeline assets support future growth.